Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment

Pharmacogenomics

Volumn 15, Issue 2, 2014, Pages 201-208

  Luo, Jian Quan ^a   Wang, Lu Yan ^b   He, Fa Zhong ^a   Sun, Ning Ling ^b   Tang, Gen Fu ^c   Wen, Jia Gen ^a   Luo, Zhi Ying ^a   Liu, Zhao Qian ^a   Zhou, Hong Hao ^a   Chen, Xiao Ping ^a   Zhang, Wei ^d  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d Institute of Clinical Pharmacology   (China)

Author keywords

antihypertensive response; enalapril; NR3C2; single nucleotide polymorphism; SNP

Indexed keywords

ENALAPRIL MALEATE; MINERALOCORTICOID RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NR3C2 PROTEIN, HUMAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NR3C2 GENE; PHARMACOGENOMICS; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST HIP RATIO; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; DRUG EFFECTS; GENETIC ASSOCIATION; GENETICS; HYPERTENSION; MIDDLE AGED; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; ENALAPRIL; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM;

EID: 84893130762     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.173     Document Type: Article

References (30)

1. Brugts JJ, den Uil CA, Danser AH, Boersma E. The renin-angiotensin- aldosterone system: Approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 112(4), 303-312 (2009).
2. Benetos A, Cambien F, Gautier S et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 28(6), 1081-1084 (1996).
3. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am. J. Hypertens. 10(8), 951-955 (1997).
4. Brugts JJ, Isaacs A, de Maat MP et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin- converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J. Hypertens. 29(3), 509-519 (2011).
5. White PC. Disorders of aldosterone biosynthesis and action. N. Engl. J. Med. 331(4), 250-258(1994).
6. Yu HM, Lin SG, Liu GZ, Zhang YQ, Ma WJ, Deng CY. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin. Pharmacol. Ther. 79(6), 581-589 (2006).
7. Yu H, Lin S, Zhang Y, Liu G. Intron-2 conversion polymorphism of the aldosterone synthase gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J. Hypertens. 26(2), 251-256 (2008).
8. Grossmann C, Benesic A, Krug AW et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol. 19(7), 1697-1710 (2005).
9. Sugiyama T, Yoshimoto T, Tsuchiya K et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146(9), 3900-3906 (2005).
10. Leopold JA, Dam A, Maron BA et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13(2), 189-197 (2007).
11. Silva PS, Fontana V, Palei AC, Sertorio JT, Biagi C, Tanus-Santos JE. Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. Eur. J. Clin. Pharmacol. 67(4), 365-370 (2011).
12. Hubert EL, Teissier R, Fernandes-Rosa FL et al. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J. Am. Soc. Nephrol. 22(11), 1997-2003 (2011).
13. Riepe FG, Finkeldei J, de Sanctis L et al. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J. Clin. Endocrinol. Metab. 91(11), 4552-4561 (2006).
14. Pujo L, Fagart J, Gary F et al. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum. Mutat. 28(1), 33-40 (2007).
15. Fernandes-Rosa FL, Hubert EL, Fagart J et al. Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1. J. Clin. Endocrinol. Metab. 96(3), E519-E527 (2011).
16. Geller DS, Farhi A, Pinkerton N et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289(5476), 119-123 (2000).
17. DeRijk RH, Wust S, Meijer OC et al. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J. Clin. Endocrinol. Metab. 91(12), 5083-5089 (2006).
18. Nossent AY, Hansen JL, Doggen C, Quax PH, Sheikh SP, Rosendaal FR. SNPs in microRNA binding sites in 3́-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am. J. Hypertens. 24(9), 999-1006 (2011).
19. Arai K, Nakagomi Y, Iketani M et al. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum. Genet. 112(1), 91-97 (2003).
20. Martinez F, Mansego ML, Escudero JC, Redon J, Chaves FJ. Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population. Am. J. Hypertens. 22(6), 649-655 (2009).
21. van Leeuwen N, Caprio M, Blaya C et al. The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension 56(5), 995-1002 (2010).
22. Galuppo P, Bauersachs J. Mineralocorticoid receptor activation in myocardial infarction and failure: Recent advances. Eur. J. Clin. Invest. 42(10), 1112-1120 (2012).
23. Kortmann GL, Contini V, Bertuzzi GP et al. The role of a mineralocorticoid receptor gene functional polymorphism in the symptom dimensions of persistent ADHD. Eur. Arch. Psychiatry Clin. Neurosci. 263(3), 181-188 (2013).
24. Sia SK, Chiou HL, Chen SC, Tsai CF, Yang SF, Ueng KC. Distribution and phenotypic expression of mineralocorticoid receptor and CYP11B2 T-344C polymorphisms in a Taiwanese hypertensive population. Mol. Biol. Rep. 40(5), 3705-3711 (2013).
25. Arnett DK, Davis BR, Ford CE et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111(25), 3374-3383 (2005).
26. Zhang X, Lynch AI, Davis BR et al. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: The GenHAT study. PLoS ONE 7(3), e34217 (2012).
27. Brugts JJ, de Maat MP, Boersma E et al. The rationale and design of the PERindopril GENEtic association study (PERGENE): A pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 23(2), 171-181 (2009).
28. Brugts JJ, Boersma E, Simoons ML. Tailored therapy of ACE inhibitors in stable coronary artery disease: Pharmacogenetic profiling of treatment benefit. Pharmacogenomics 11(8), 1115-1126 (2010).
29. Silva PS, Fontana V, Luizon MR et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur. J. Clin. Pharmacol. 69(2), 167-177 (2013).
30. Matayoshi T, Kamide K, Takiuchi S et al. The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res. 27(11), 821-833 (2004).